The latest price target for Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE:BIO/B) was reported by Wells Fargo on August 27, 2024. The analyst firm set a price target for $340.00 expecting BIO/B to fall to within 12 months (a possible -12.89% downside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE:BIO/B) was provided by Wells Fargo, and Bio-Rad Laboratories, Inc. Class B Common Stock initiated their equal-weight rating.

There is no last upgrade for Bio-Rad Laboratories, Inc. Class B Common Stock

The last downgrade for Bio-Rad Laboratories, Inc. Class B Common Stock happened on April 3, 2024 when Citigroup changed their price target from $400 to $365 for Bio-Rad Laboratories, Inc. Class B Common Stock.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bio-Rad Laboratories, Inc. Class B Common Stock, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bio-Rad Laboratories, Inc. Class B Common Stock was filed on August 27, 2024 so you should expect the next rating to be made available sometime around August 27, 2025.

While ratings are subjective and will change, the latest Bio-Rad Laboratories, Inc. Class B Common Stock (BIO/B) rating was a initiated with a price target of $0.00 to $340.00. The current price Bio-Rad Laboratories, Inc. Class B Common Stock (BIO/B) is trading at is $390.29, which is out of the analyst’s predicted range.